Table 1.
Clinical Characteristics of the Study Group
| P | |||||||
|---|---|---|---|---|---|---|---|
| All | A -CMR |
B +CMR-S |
C +CMR+S |
B vs A | C vs A | C vs B | |
| N | 559 | 350 | 166 | 43 | |||
| Age, yrs | 70.4 ± 10.7 | 71.6 ± 10.7 | 68.3 ± 10.6 | 68.5 ± 10.6 | 0.0007 | 0.0704 | 0.8714 |
| Men, n (%) | 436 (78) | 275 (79) | 123 (74) | 38 (88) | 0.1203 | ||
| NYHA class | 3.31 ± 0.5 | 3.35 ± 0.5 | 3.20 ± 0.40 | 3.37 ± 0.49 | 0.0004 | 0.8115 | 0.0287 |
| III | 385 (69) | 225 (64) | 133 (80) | 27 (63) | |||
| CRT-D, n (%) | 87 (16) | 52 (15) | 27 (16) | 8 (19) | 0.7799 | ||
| Co-morbidity, No. (%) | |||||||
| Diabetes mellitus | 90 (16) | 55 (16) | 25 (15) | 10 (24) | 0.4248 | ||
| Hypertension | 149 (27) | 93 (17) | 44 (27) | 12 (28) | 0.9575 | ||
| Coronary artery bypass | 112 (20) | 65 (19) | 30 (18) | 17 (40) | 0.0048 | ||
| Medication, No. (%) | |||||||
| Loop diuretics | 495 (89) | 314 (90) | 144 (87) | 37 (86) | 0.2619 | ||
| ACE-I or ARB | 498 (89) | 306 (87) | 151 (91) | 41 (95) | 0.3392 | ||
| Beta-blockers | 300 (54) | 177 (51) | 97 (58) | 26 (60) | 0.2641 | ||
| Spironolactone | 224 (40) | 138 (39) | 65 (39) | 17 (40) | 0.9142 | ||
| ECG variables | |||||||
| Chronic atrial fibrillation, No. (%) |
119 (21) | 86 (25) | 29 (17) | 4 (9) | 0.0249 | ||
| QRS duration, ms | 154.3 ± 28.5 | 158.5 ± 29.5 | 148.6 ± 25.4 | 144.5 ± 26.0 | 0.0003 | 0.0022 | 0.3860 |
| Echocardiography | |||||||
| LVEDV, mL | 259.0 ± 109.0 | 252.5 ± 107.2 | 268.3 ± 115.1 | 267.5 ± 97.2 | 0.1938 | 0.4489 | 0.9703 |
| LVESV, mL | 200.9 ± 94.5 | 196.5 ± 92.2 | 207.2 ± 101.2 | 206.0 ± 83.8 | 0.3109 | 0.5820 | 0.9466 |
| LVEF, % | 23.5 ± 10.1 | 23.2 ± 10.4 | 24.1 ± 9.9 | 23.7 ± 8.6 | 0.4346 | 0.7832 | 0.8465 |
+CMR-S = CMR showing no scar at the LV pacing position; +CMR+S = CMR showing scar at the LV pacing position; -CMR = non-CMR guided group.